Review: risperidone produces more clinical improvement and causes fewer extrapyramidal side effects in schizophrenia


Objective
To evaluate the effectiveness, using meta-analysis, of risperidone compared with “conventional” neuroleptic drugs in patients with schizophrenia.

Data sources
Studies were identified using Medline, Biological Abstracts, Embase, PsycLIT, and the Cochrane Library; reviewing the references of published studies; and contacting pharmaceutical companies for data on unpublished trials.

Study selection
Studies were selected if they were randomised controlled trials that compared risperidone with other conventional neuroleptic agents (haloperidol in 10 studies) for schizophrenia or schizophrenia like psychosis (schizophreniform and schizoaffective disorders).

Data extraction
Data were extracted on patient characteristics, diagnosis and duration of illness, antipsychotic drug types, and dosages. Main outcome measures were clinical improvement (measured as: (1) 20% reduction in total score on the Positive and Negative Symptom Rating Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS); (2) “clinically improved” on the Clinical Global Impression (CGI) scale), extrapyramidal side effects (EPS), and acceptability of treatment (drop out rate).

Main results
12 studies (2696 patients) (mean age 37 y, 70% men, mean time since onset of symptoms 15 y, mean of 6 previous admissions) met the inclusion criteria. 1857 patients received risperidone, 574 received haloperidol, 123 received other conventional neuroleptics, and 142 received placebo. Risperidone led to greater clinical improvement when measured by the PANSS and BPRS (10 studies) p < 0.003 but not by the CGI scale (6 studies) p = 0.13* (table). Fewer patients who received risperidone had EPS (8 studies) p < 0.001* and the drop out rate was reduced with risperidone (12 studies) p = 0.005* (table).

Conclusion
Risperidone produces greater clinical improvement than conventional neuroleptic agents in patients with schizophrenia and is associated with fewer extrapyramidal side effects.

*p values calculated from data in article.

Risperidone v conventional neuroleptics†

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Risperidone weighted EER</th>
<th>Neuroleptics weighted EER</th>
<th>RBI (95% CI)</th>
<th>Weighted ABI</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical improvement</td>
<td>58.6%</td>
<td>51.4%</td>
<td>1%</td>
<td>7.2%</td>
<td>14</td>
</tr>
<tr>
<td>CGI scale</td>
<td>62%</td>
<td>57.3%</td>
<td>9%</td>
<td>4.7%</td>
<td>(CI 1.3 to 10.6)</td>
</tr>
<tr>
<td>EPS</td>
<td>62%</td>
<td>42.5%</td>
<td>37%</td>
<td>14.5%</td>
<td>7</td>
</tr>
<tr>
<td>Dropout rate</td>
<td>27.7%</td>
<td>33.4%</td>
<td>18%</td>
<td>5.7%</td>
<td>(11 to 58)</td>
</tr>
</tbody>
</table>

† CGI = clinical global impression; EPS = extrapyramidal side effects; PANSS = Positive and Negative Symptom Rating Scale; BPRS = Brief Psychiatric Rating Scale; NS = not significant. Other abbreviations defined in glossary; RBI, ABI, RRR, ARR, NNT, and CI calculated from data in article.

Sources of funding: Centre for Health Economics, University of York; Greater Glasgow Community and Mental Health Services NHS Trust; Research and Development Directorate, Glasgow.

For article reprint: Dr E Kennedy, Research and Development Directorate, Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow G12 0XH, UK. Fax +44 (0)141 211 3814.

Commentary
The review by Kennedy et al provides useful information on the effectiveness of risperidone compared with conventional neuroleptics (mainly haloperidol) in patients with chronic schizophrenia. The reviewers increased the robustness of their conclusions by including only randomised controlled trials. One of the main contributions of the review is to highlight the clear limitations of the primary studies. Most of the trials studied patients for < 12 weeks and all but 1 trial randomised only patients with chronic schizophrenia and used a cut off of 20% in rating scales (BPRS and PANSS) to measure improvement. No suitable information regarding clinically meaningful outcomes such as relapse, hospitalisation, quality of life, social functioning, or employment status of the patients was provided by the original trials. The absence of cost data precluded an analysis of the cost effectiveness of risperidone. Additionally, although risperidone seems to cause fewer EPS, this medication was compared with a fixed or high dose of haloperidol (which may be more likely to cause EPS than other conventional neuroleptics), and specific information about drug induced movement disorders was given in only 2 trials.1 2

Risperidone seems to improve the clinical symptoms of patients with chronic schizophrenia in the short term (< 12 weeks), causes fewer EPS, and leads to less discontinuation. However, 14 patients must be treated with risperidone, rather than haloperidol, for 1 additional patient to achieve a 20% reduction in BPRS or PANSS score. It is unclear whether this result is clinically meaningful or if such results will remain the same over a long term treatment period. Doubts remain regarding the cost effectiveness of this medication and no clear statement can be made about its effect on the positive or negative symptoms of schizophrenia.

Karla V S Soares, MD, MSc, PhD
Federal University of São Paulo
São Paulo, Brazil